What Fueled The Previous Growth In The Next Generation Drug Conjugates Market?
The next generation drug conjugates market has seen considerable growth due to a variety of factors.
• The market size for next-generation drug conjugates has witnessed swift growth in the recent past. The predictions suggest an expansion from $2.15 billion in 2024 to $2.5 billion in 2025, with a compound annual growth rate (CAGR) of 16.3%.
The growth observed during the historic period can be due to an elevated comprehension of tumor biology, positive outcomes of initial drug conjugates, an increase in oncology, augmented investments and financing, along with heightened patient advocacy and consciousness.
What Is The Expected Growth In The Next Generation Drug Conjugates Market Size Evolve over the Forecast Period?
The next generation drug conjugates market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for next-generation drug conjugates is poised for rapid escalation in the coming years, with projections reaching $4.53 billion by 2029, growing at a compound annual growth rate (CAGR) of 16.0%.
Multiple factors contribute to this rise during the forecast period, including the expansion of combination therapies, amplified clinical research, focus on rare ailments, strategic partnerships, and the advent of new bioinformatics tools. Key trends for the forecast period comprise further advancements in monoclonal antibody technology, combination therapies using JAK inhibitors, the application of artificial intelligence to drug development, the growth of biosimilars, and progress in subcutaneous formulations.
What Main Forces Are Fueling Expansion In The Next Generation Drug Conjugates Market?
The surge in cancer incidence is anticipated to drive the expansion of the next-generation drug conjugates market. Cancer, a collection of diseases marked by unchecked expansion and distribution of irregular cells in the body, is primarily escalating due to an aging society, lifestyle aspects, environmental factors, enhanced detection, genetic elements, and infectious agents. Next-generation drug conjugates offer a solution to cancer by directing therapies straight to cancer cells, thereby sharpening treatment effectiveness and lessening damage to normal tissues. As an example, a report from the Australian Institute of Health and Welfare in August 2024 highlighted that by 2034, it is expected that Australia will see about 209,000 new cancer diagnoses, a substantial rise from the predicted 169,000 cases in 2024. This demonstrates the effect of an expanding population and increasing cancer rates. Consequently, the escalating incidence of cancer is fuelling the expansion of the next-generation drug conjugates market.
What Are The Primary Segments In The Global Next Generation Drug Conjugates Market?
The next generation drug conjugatesmarket covered in this report is segmented –
1) By Next-Generation Drug Conjugates Type: Peptide Receptor Radionuclide Therapy, Ligand Mediated RNAI Conjugate, Ligand Conjugated Anti Sense Medicine, Peptide Drug Conjugate
2) By Targeting Ligand Type: Amino Sugar, Lipid, Peptide, Small Molecule, Virus-Like Particles
3) By Payload Type: Oligonucleotide, Radionuclide, Peptide, Small Molecule
4) By Therapy: Monotherapy, Combination Therapy
5) By Indication: Gastroenteropancreatic Neuroendocrine Tumors, Prostate Cancer, Leptomeningeal Carcinomatosis Caused By Breast Cancer Brain Metastases, Hereditary Transthyretin Amyloidosis, Atherosclerotic Cardiovascular Diseases, Severe Hypertriglyceridemia, Hereditary Angioedema, Acute Hepatic Porphyria, Other Indications
Subsegments:
1) By Peptide Receptor Radionuclide Therapy (PRRT): Somatostatin Analogues, Radiolabeled Peptides
2) By Ligand Mediated RNAi Conjugate: SiRNA Ligand Conjugates, ShRNA Ligand Conjugates
3) By Ligand Conjugated Anti-Sense Medicine: Oligonucleotide Ligand Conjugates, Antisense Oligonucleotide Ligand Conjugates
4) By Peptide Drug Conjugate: Cytotoxic Peptide Conjugates, Therapeutic Peptide Conjugates
Pre-Book The Next Generation Drug Conjugates Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Next Generation Drug Conjugates Market?
Prominent corporations in the next-generation drug conjugates market are leveraging strategic collaborations with the goal of improving their research and development capacities, fast-tracking product innovation, and extending their market influence. This notion of strategic partnerships is about companies making the most of each other's capabilities and resources for mutual prosperity and accomplishment. To illustrate, Prelude Therapeutics Incorporated, an American clinical-stage precision oncology firm, established a business relationship with AbCellera Biologics Inc., a Canadian biotechnology firm, in November 2023 to venture into the production of pioneering precision antibody-drug conjugates (ADCs) primarily for oncology. The focus of this collaboration is on the inception, progression, and marketing of advanced antibody-drug conjugates (ADCs), initiating with a scheme targeting a SMARCA degrader related to a new antibody. The strategy aims to apply Prelude's small-molecule SMARCA2 selective degraders in a wider therapeutic framework, especially for patients with cancers that do not involve SMARCA4 mutations.
Who Are the Key Players In The Next Generation Drug Conjugates Market?
Major companies operating in the next generation drug conjugates marker are:
• Pfizer Inc.
• Johnson & Johnson
• Merck & Co. Inc.
• AbbVie Inc.
• Novartis International AG
• AstraZeneca PLC
• Daiichi Sankyo Company Limited
• Eisai Co Ltd.
• Bicycle Therapeutics plc
• Zymeworks Inc.
• Genentech Inc.
• MacroGenics Inc.
• Abzena plc
• Innate Pharma S.A.
• CytomX Therapeutics Inc.
• ImmunoGen Inc.
• Ascentage Pharma Group International
• Mersana Therapeutics Inc.
• Antengene Corporation Limited
• Nurix Therapeutics Inc.
• Tubulis GmbH
What Is The Most Dominant Region In The Next Generation Drug Conjugates Market?
North America was the largest region in the next generation drug conjugates market in 2024. The regions covered in the next generation drug conjugates marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
